NHS Devon - Medicines Optimisation Services

Concepts

• pharmacy services
• exeter
• key medicines optimisation priorities
• nhs devon
• medicines budgets
• medicines optimisation services
• nhs commissioners
• nhs south
• nhs
• medicines optimisation services for nhs devon

Location

Exeter

Description

The subscription to the Medicines Optimisation Service will provide a comprehensive set of resources to support the medicines optimisation cost improvement programmes and to further support the implementation of key medicines optimisation priorities for NHS Devon.

Total Quantity or Scope

The subscription to the Medicines Optimisation Service provides a comprehensive set of resources to support the medicines optimisation cost improvement programmes and to further support the implementation of key medicines optimisation priorities for NHS Devon. The Medicines Optimisation Service supports NHS commissioners to improve patient outcomes and manage medicines budgets effectively. It also supports collaboration across the NHS and therefore reduces duplication. NHS Devon is looking to award a Medicines Optimisation Service to PrescQIPP, the incumbent provider, using the Direct Award C process under the Health Care Services (Provider Selection Regime) Regulations 2023 (the 'Regulations'). The subscription to Medicines Optimisation Services for NHS Devon is considered a Pharmacy Service and is subject to the Regulations that came into force on 1st January 2024. The contract will be for a 2-year period with the option to extend for a further 1-year period. The total value of the contract including the extension period is £96,854 (excl VAT). This procurement has been carried out by NHS South, Central and West Commissioning Support Unit (SCW) on behalf of the Commissioners.

Award Detail

Renewal Options

The contract will be for a 2-year period with the option to extend for a further 1-year period.

Award Criteria

CPV Codes

• 85149000 - Pharmacy services

Indicators

• Options are available.
• Award on basis of price and quality.

Legal Justification

This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be made to the relevant authority via the email address scwcsu.clinical.procurement@nhs.net by midnight (23:59) on 19/4/2024. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.

Other Information

The existing provider is satisfying the original contract and will likely satisfy the proposed contract to a sufficient standard. This is a Provider Selection Regime (PSR) intention to award notice (via Direct Award C). The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award. The publication of this notice marks the start of the standstill period. Representations by providers must be submitted to the relevant authority via the email address scwcsu.clinical.procurement@nhs.net by midnight (23:59) on 19/4/2024. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR. Decision Makers: NHS Devon Senior Leadership Team NHS Devon Primary Care Medicines Optimisation Group Approval was granted on 11th January 2024 via a Procurement Approach Record signed by the Head of Contracting to ensure compliance with NHS Devon's procurement policy. The Key Criteria and Evaluation Methodology was reviewed by the NHS Devon Senior Leadership Team on 23rd February 2024 and approved by the Primary Care Medicines Optimisation Group on 28th February 2024. The scoring of current and likely future performance of the contract was reviewed by the NHS Devon Senior Leadership Team on 21st March 2024 and approved by the Primary Care Medicines Optimisation Group on 27th March 2024. The Decision Making record was approved by the NHS Devon Head of Contracting on 28th March 2024. No conflicts of interest were declared. NHS Devon considered the five key criteria as stated in the Regulations when applying Direct Award Process C and authorised the following weightings on 28th February 2024: - Quality and Innovation (30%) - Value (40%) - Integration, collaboration and service sustainability (10%) - Improving access, reducing health inequalities and facilitating choice (10%) - Social Value (10%) The value criteria was weighted heaviest to recognise the importance of the return on investment that a Medicines Optimisation Service realises through prescribing cost savings and rebates achieved, the tangible impact made to the management of medicines budgets and the saving made in relation to staff time. Quality and Innovation was weighted the second highest due to the requirement to have a service that results in increased quality and innovation for NHS Devon. The other criteria were weighted equally at 10%. The Integration, collaboration and service sustainability criteria ensured consideration of the ICB, GP practices, Community Pharmacists, Primary Care Networks, Acute, Community and Mental Health Trusts, and care homes. With prescribing being the second highest area of expenditure in the NHS, the provider has to have a positive impact on the financial sustainability of prescribing. The Improving access, reducing health inequalities and facilitating choice criteria looked at effective contributions to safe and effective treatments being prescribed to patients and improving outcomes. Social value was considered with assessment of policies and practices aligning with moving towards net zero and supporting broader social, environmental, and economic development. The incumbent provider was assessed against these key criteria in relation to current performance against the existing contract and likely future performance of the contract. The incumbent provider has been satisfying the existing contract to a sufficient standard and has provided excellent return on investment, demonstrated excellent quality control to provide resources with the necessary evidence base with suitably qualified and experienced individuals in place. The provider has a workplan with a number of projects to be delivered over the next three years. The quality assurance process will remain the same and further efficiency savings have been projected.